Eli Lilly and Co. (LLY) announced Wednesday that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry.
Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through July 2024. An internal and external search for her successor is actively underway.
Prior to serving as Lilly's CFO, Ashkenazi was senior vice president, controller, and chief financial officer of Lilly Research Laboratories. In this role, she oversaw the CFOs of the company's commercial businesses, as well as those for research and development, manufacturing and quality, and G&A functions.
She also led the corporate strategy team and business transformation office. Previously, she served as CFO for several of the company's global business areas.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.